1
|
Jiang L, Wang S, Zhao J, Chien C, Zhang Y, Su G, Chen X, Song D, Chen Y, Huang W, Xiao Y, Cao Y, Hu Z. Treatment options of traditional Chinese patent medicines for dyslipidemia in patients with prediabetes: A systematic review and network meta-analysis. Front Pharmacol 2022; 13:942563. [PMID: 36105194 PMCID: PMC9465834 DOI: 10.3389/fphar.2022.942563] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2022] [Accepted: 07/21/2022] [Indexed: 11/13/2022] Open
Abstract
Objective: To compare the clinical efficacy and safety of SIX Traditional Chinese Patent Medicines (TCPM) recommended by guidelines in improving lipids for patients with prediabetes by network meta-analysis. Methods: Randomized controlled trials of 6 TCPM in the treatment of prediabetes were searched systematically in various databases. After extracting effective data, the risk of bias was assessed using Review Manager 5.3 and Cochrane Collaboration Systems Evaluator's Manual. Network meta-analysis was performed using STATA 15.0 based on the frequency statistical model. The effect size and credibility of the evidence for the intervention were summarized based on a minimal contextualized framework. Results: A total of 27 studies involving 2,227 patients were included. Compared with lifestyle modification (LM), Shenqi + LM [SMD -0.49 (95% CI: -0.85, -0.12)] and Jinqi + LM [SMD -0.44 (95% CI: -0.81, -0.06)] showed statistically significant effect in lowering TG, Shenqi + LM [SMD -0.51 (95%CI: -0.86, -0.17)] and Jinqi + LM [SMD -0.44 (95%CI: -0.80, -0.08)] in lowering TC, Jinlida + LM [SMD -0.31 (95%CI: -0.59, -0.04)] in lowering LDL-C, Shenqi + LM [SMD 0.29 (95%CI: 0.06, 0.51)] and Jinqi + LM [SMD 0.16 (95%CI: 0.01, 0.31)] in increasing HDL-C. Conclusion: For patients with prediabetes, Traditional Chinese patent medicine Jinqi and Shenqi combined with lifestyle modification were associated with a significant reduction in TG and TC, while Shenqi + LM was among the most effective. Jinlida + LM was among the least effective. Systematic Review Registration: https://clinicaltrials.gov/, identifier PROSPERO(CRD42021279332).
Collapse
Affiliation(s)
- Li Jiang
- Section II of Endocrinology and Nephropathy Department of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China
| | - Shidong Wang
- Section II of Endocrinology and Nephropathy Department of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China
| | - Jinxi Zhao
- Section II of Endocrinology and Nephropathy Department of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China
| | - Chieh Chien
- Department of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland
| | - Yaofu Zhang
- Section II of Endocrinology and Nephropathy Department of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China
| | - Guanxun Su
- Section II of Endocrinology and Nephropathy Department of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China
| | - Xiaoyu Chen
- Section II of Endocrinology and Nephropathy Department of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China
| | - Dechao Song
- Section II of Endocrinology and Nephropathy Department of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China
| | - Yu Chen
- Section II of Endocrinology and Nephropathy Department of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China
| | - Weijun Huang
- Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China
| | - Yonghua Xiao
- Section II of Endocrinology and Nephropathy Department of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China
| | - Yandong Cao
- Section II of Endocrinology and Nephropathy Department of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China
| | - Zixian Hu
- Section II of Endocrinology and Nephropathy Department of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China
| |
Collapse
|
2
|
Cheng Y, Dai R, Chen W, Li Q, Zhang C, Yang T. Genetic polymorphisms of pharmacogenomic VIP variants in the Dai population from Yunnan province. Mol Genet Genomic Med 2020; 8:e1231. [PMID: 32347657 PMCID: PMC7336744 DOI: 10.1002/mgg3.1231] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2020] [Revised: 02/04/2020] [Accepted: 02/24/2020] [Indexed: 12/17/2022] Open
Abstract
Background Pharmacogenomics plays a crucial role in individualized therapy, but the variant information of pharmacogenomics in the Dai population is limited. We therefore aimed to screen very important pharmacogenetic (VIP) in the Dai population and compared differences between Dai and other 25 populations. Methods In this study, we genotyped 73 VIP variants from the PharmGKB and compared genotype distribution of variants in Dai with other 25 populations by χ2 test. To assess the genetic relationship among 26 populations, we performed the structure analysis. In addition, pair‐wise F‐statistics (Fst) was calculated to measure the population differentiation. Results We found 12, 10, 13, 17, 11, 39, 46, 46, 45, 43, 49, 46, 46, 46, 49, 45, 41, 42, 48, 53, 45, 50, 50, 51, 47, and 50 significantly different variants in Dai compared with other 25 populations. Genetic structure analysis showed Dai had close relationships with CDX (Chinese Dai in Xishuangbanna), CHB (Han Chinese in Beijing), JPT (Japanese in Tokyo), and KHV (Kinh in Ho Chi Minh City, Vietnam). Moreover, Dai is the most similar to KHV according to Fst analysis. Conclusions Our study complement the pharmacogenomics information of Dai population from Yunnan province and provide a theoretical basis for personalized medicine.
Collapse
Affiliation(s)
- Yujing Cheng
- Department of Blood TransfusionThe First People’s Hospital of Yunnan ProvinceYunnan ProvinceKunmingChina
| | - Run Dai
- Department of Blood TransfusionThe First People’s Hospital of Yunnan ProvinceYunnan ProvinceKunmingChina
| | - Wanlu Chen
- Department of Blood TransfusionThe First People’s Hospital of Yunnan ProvinceYunnan ProvinceKunmingChina
| | - Qi Li
- Department of Blood TransfusionThe First People’s Hospital of Yunnan ProvinceYunnan ProvinceKunmingChina
| | - Chan Zhang
- Department of Blood TransfusionThe First People’s Hospital of Yunnan ProvinceYunnan ProvinceKunmingChina
| | - Tonghua Yang
- Department of HematologyThe First People’s Hospital of Yunnan ProvinceYunnan ProvinceKunmingChina
| |
Collapse
|
3
|
Han CY, Liu J, Wan F, Tian M, Zhang YL, He QH, Si YC. Effects of Tianqijiangtang capsule on survival, self-renewal and differentiation of hippocampal neural stem cells of embryonic rats cultured in high glucose medium. Am J Transl Res 2019; 11:5560-5572. [PMID: 31632529 PMCID: PMC6789250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2019] [Accepted: 05/30/2019] [Indexed: 06/10/2023]
Abstract
OBJECTIVE This study aims to investigate the effects of Tianqijiangtang capsule on the survival, self-renewal and differentiation of hippocampal neural stem cells (NSCs) of embryonic rats cultured in high glucose medium. MATERIALS AND METHODS A cell model of diabetic encephalopathy was established. Cell viability was assessed to screen the optimal concentration of glucose for the cell model of diabetic encephalopathy. Then, the effects of Tianqijiangtang capsule on the proliferation and differentiation of NSCs, and the expression of vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF) in the culture medium and cells were detected. RESULTS High glucose significantly reduced the ability of survival, proliferation and differentiation of NSCs, which was statistically significant, when compared to the control group (P < 0.05 or 0.01). Tianqijiangtang capsule significantly enhanced the survival, proliferation and differentiation of NSCs cultured in high glucose medium, which was statistically significant, when compared with the high glucose group (P < 0.05 or 0.01). The high glucose culture resulted in a significant decrease in VEGF and BDNF levels in culture medium and cells of NSCs. Tianqijiangtang capsule significantly increased the level of VEGF nuclear BDNF in cells and the culture medium, which was significantly higher, when compared to that in the high glucose group (P < 0.05 or 0.01). CONCLUSION Tianqijiangtang capsule enhances the level of neurotrophic factor synthesized and secreted by hippocampal NSCs cultured with high glucose through the autocrine and paracrine pathway, promotes the NSC survival, replication and differentiation of new neurons and astrocytes, and reduces the degeneration and necrosis of nerve cells.
Collapse
Affiliation(s)
- Chun-Yong Han
- Department of Sub-Health of TCM, School of Traditional Chinese Medicine, Hunan University of Chinese MedicineChangsha 410208, China
| | - Jing Liu
- Ben Best Medical Science & Technology (Beijing) Co., Ltd.Beijing 100036, China
| | - Feng Wan
- Department of Anatomy, School of Traditional Chinese Medicine, Beijing University of Chinese MedicineBeijing 100029, China
| | - Mo Tian
- Department of Anatomy, School of Traditional Chinese Medicine, Beijing University of Chinese MedicineBeijing 100029, China
| | - Yan-Li Zhang
- Department of Anatomy, School of Traditional Chinese Medicine, Beijing University of Chinese MedicineBeijing 100029, China
| | - Qing-Hu He
- Department of Sub-Health of TCM, School of Traditional Chinese Medicine, Hunan University of Chinese MedicineChangsha 410208, China
| | - Yin-Chu Si
- Department of Anatomy, School of Traditional Chinese Medicine, Beijing University of Chinese MedicineBeijing 100029, China
| |
Collapse
|
4
|
Al-Eitan LN, Mohammad NN, Al-Maqableh HW, Hakooz NM, Dajani RB. Genetic Polymorphisms of Pharmacogenomic VIP Variants in the Circassian Subpopulation from Jordan. Curr Drug Metab 2019; 20:674-681. [PMID: 31362667 DOI: 10.2174/1389200220666190729124000] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2019] [Revised: 05/27/2019] [Accepted: 07/01/2019] [Indexed: 12/11/2022]
Abstract
BACKGROUND It has been suggested that genetic variation within candidate pharmacogenes contributes to the differences in drug safety and efficacy as well as risk of adverse drug reactions among different ethnic groups. Illustrating the polymorphic distribution of Very Important Pharmacogenes (VIPs) in various ethnic groups will contribute to the development of personalized medicine for those populations. OBJECTIVE The present study aimed to identify the polymorphic distribution of VIPs in the Circassian subpopulation of Jordan and compare their allele frequencies with those of other populations. METHODS A total of 130 healthy and unrelated Circassian adults from Jordan were randomly recruited and genotyped for eleven VIP variants within the thiopurine S-methyltransferase (TPMT), ATP-binding cassette, sub-family B, member 1 (ABCB1), and vitamin D receptor (VDR) genes via Sequenom's MassARRAY® genotyping platform (iPLEX GOLD). RESULTS Our data on the allelic frequencies of the investigated VIP variants were compared to those of 18 other populations, comprising 11 HapMap populations, 6 Exome Aggregation Consortium populations, and the Chechen- Jordanian population from Jordan. Circassian-Jordanians were found to most resemble the African, Chechen- Jordanian, European (Finnish), European (non-Finnish), and South-Asian populations. CONCLUSION Circassians from Jordan significantly differ from other populations in terms of the allelic frequencies of selected VIP variants. The present findings constitute the first set of pharmacogenetic data for Circassian population from Jordan, providing a basis for safe drug administration that may be useful in diagnosing and treating diseases in this ethnic group.
Collapse
Affiliation(s)
- Laith N Al-Eitan
- Department of Applied Biological Sciences, Jordan University of Science and Technology, Irbid 22110, Jordan.,Department of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid 22110, Jordan
| | - Namarg N Mohammad
- Department of Applied Biological Sciences, Jordan University of Science and Technology, Irbid 22110, Jordan
| | - Haneen W Al-Maqableh
- Department of Biology and Biotechnology, Hashemite University, Zarqa 13133, Jordan
| | - Nancy M Hakooz
- Department of Biopharmaceutics and Clinical Pharmacy, School of Pharmacy, University of Jordan, Amman 11942, Jordan
| | - Rana B Dajani
- Department of Biology and Biotechnology, Hashemite University, Zarqa 13133, Jordan.,Radcliffe Institute for Advanced Studies, Harvard University, Cambridge, 02138 MA, United States
| |
Collapse
|
5
|
Ilyas M, Kim JS, Cooper J, Shin YA, Kim HM, Cho YS, Hwang S, Kim H, Moon J, Chung O, Jun J, Rastogi A, Song S, Ko J, Manica A, Rahman Z, Husnain T, Bhak J. Whole genome sequencing of an ethnic Pathan (Pakhtun) from the north-west of Pakistan. BMC Genomics 2015; 16:172. [PMID: 25887915 PMCID: PMC4362645 DOI: 10.1186/s12864-015-1290-1] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2014] [Accepted: 01/29/2015] [Indexed: 11/10/2022] Open
Abstract
Background Pakistan covers a key geographic area in human history, being both part of the Indus River region that acted as one of the cradles of civilization and as a link between Western Eurasia and Eastern Asia. This region is inhabited by a number of distinct ethnic groups, the largest being the Punjabi, Pathan (Pakhtuns), Sindhi, and Baloch. Results We analyzed the first ethnic male Pathan genome by sequencing it to 29.7-fold coverage using the Illumina HiSeq2000 platform. A total of 3.8 million single nucleotide variations (SNVs) and 0.5 million small indels were identified by comparing with the human reference genome. Among the SNVs, 129,441 were novel, and 10,315 nonsynonymous SNVs were found in 5,344 genes. SNVs were annotated for health consequences and high risk diseases, as well as possible influences on drug efficacy. We confirmed that the Pathan genome presented here is representative of this ethnic group by comparing it to a panel of Central Asians from the HGDP-CEPH panels typed for ~650 k SNPs. The mtDNA (H2) and Y haplogroup (L1) of this individual were also typical of his geographic region of origin. Finally, we reconstruct the demographic history by PSMC, which highlights a recent increase in effective population size compatible with admixture between European and Asian lineages expected in this geographic region. Conclusions We present a whole-genome sequence and analyses of an ethnic Pathan from the north-west province of Pakistan. It is a useful resource to understand genetic variation and human migration across the whole Asian continent. Electronic supplementary material The online version of this article (doi:10.1186/s12864-015-1290-1) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Muhammad Ilyas
- National Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan. .,Personal Genomics Institute, Genome Research Foundation, Suwon, Republic of Korea.
| | - Jong-Soo Kim
- Theragen Bio Institute, TheragenEtex, Suwon, Republic of Korea.
| | - Jesse Cooper
- Theragen Bio Institute, TheragenEtex, Suwon, Republic of Korea.
| | - Young-Ah Shin
- Theragen Bio Institute, TheragenEtex, Suwon, Republic of Korea.
| | - Hak-Min Kim
- Personal Genomics Institute, Genome Research Foundation, Suwon, Republic of Korea. .,The Genomics Institute, Biomedical Engineering Department, UNIST, Ulsan, Republic of Korea.
| | - Yun Sung Cho
- Personal Genomics Institute, Genome Research Foundation, Suwon, Republic of Korea. .,The Genomics Institute, Biomedical Engineering Department, UNIST, Ulsan, Republic of Korea.
| | - Seungwoo Hwang
- Korean Bioinformation Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.
| | - Hyunho Kim
- The Genomics Institute, Biomedical Engineering Department, UNIST, Ulsan, Republic of Korea.
| | - Jaewoo Moon
- Theragen Bio Institute, TheragenEtex, Suwon, Republic of Korea.
| | - Oksung Chung
- Personal Genomics Institute, Genome Research Foundation, Suwon, Republic of Korea.
| | - JeHoon Jun
- Personal Genomics Institute, Genome Research Foundation, Suwon, Republic of Korea.
| | - Achal Rastogi
- Personal Genomics Institute, Genome Research Foundation, Suwon, Republic of Korea.
| | - Sanghoon Song
- Theragen Bio Institute, TheragenEtex, Suwon, Republic of Korea.
| | - Junsu Ko
- Theragen Bio Institute, TheragenEtex, Suwon, Republic of Korea.
| | - Andrea Manica
- Department of Zoology, University of Cambridge, Downing Street, Cambridge, CB2 3EJ, UK.
| | - Ziaur Rahman
- National Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan.
| | - Tayyab Husnain
- National Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan.
| | - Jong Bhak
- Personal Genomics Institute, Genome Research Foundation, Suwon, Republic of Korea. .,Theragen Bio Institute, TheragenEtex, Suwon, Republic of Korea. .,The Genomics Institute, Biomedical Engineering Department, UNIST, Ulsan, Republic of Korea.
| |
Collapse
|
6
|
Liu MZ, Zhang YL, Zeng MZ, He FZ, Luo ZY, Luo JQ, Wen JG, Chen XP, Zhou HH, Zhang W. Pharmacogenomics and herb-drug interactions: merge of future and tradition. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE : ECAM 2015; 2015:321091. [PMID: 25821484 PMCID: PMC4363646 DOI: 10.1155/2015/321091] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 12/01/2014] [Revised: 01/20/2015] [Accepted: 01/21/2015] [Indexed: 12/16/2022]
Abstract
The worldwide using of herb products and the increasing potential herb-drug interaction issue has raised enthusiasm on discovering the underlying mechanisms. Previous review indicated that the interactions may be mediated by metabolism enzymes and transporters in pharmacokinetic pathways. On the other hand, an increasing number of studies found that genetic variations showed some influence on herb-drug interaction effects whereas these genetic factors did not draw much attention in history. We highlight that pharmacogenomics may involve the pharmacokinetic or pharmacodynamic pathways to affect herb-drug interaction. We are here to make an updated review focused on some common herb-drug interactions in association with genetic variations, with the aim to help safe use of herbal medicines in different individuals in the clinic.
Collapse
Affiliation(s)
- Mou-Ze Liu
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
- Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha 410078, China
| | - Yue-Li Zhang
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
- Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha 410078, China
| | - Mei-Zi Zeng
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
- Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha 410078, China
| | - Fa-Zhong He
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
- Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha 410078, China
| | - Zhi-Ying Luo
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
- Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha 410078, China
| | - Jian-Quan Luo
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
- Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha 410078, China
| | - Jia-Gen Wen
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
- Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha 410078, China
| | - Xiao-Ping Chen
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
- Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha 410078, China
| | - Hong-Hao Zhou
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
- Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha 410078, China
| | - Wei Zhang
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
- Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha 410078, China
| |
Collapse
|